Cell and Developmental Biology Commons^™

Impact Of Pre-Transplant Induction Therapy On Outcomes Of Patients Who Undergo Autologous Stem Cell Transplantation For Mantle Cell Lymphoma In First Complete Remission, Omar Albanyan, Samer Alkassis, Seongho Kim, Andrew Kin, Asif Alavi, Lois Ayash, Voravit Ratanatharathorn, Dipenkumar Modi, Joseph P. Uberti, Abhinav Deol

Hematology/Oncology and Stem Cell Therapy

Mantle cell lymphoma is a rare subtype of non-Hodgkin’s lymphoma with poor prognosis and continue to be challenging to treat. The choice of first line induction regimen remains a topic of debate due paucity of clinical trials. We retrospectively evaluated 66 patients diagnosed with mantle cell lymphoma who achieved first complete response after induction chemotherapy followed by autologous stem cell transplant. Treatment groups were divided into lowintensity versus high-intensity regimens. Our data showed the intensity of induction regimen does not impact posttransplant outcomes of mantle cell lymphoma who underwent autologous stem cell transplant in first complete response.

Promising Effect Of Pdl1 Inhibitors In The Front-Line Management Of Primary Aggressive Central Nervous System Lymphoma: A Case Report, Rasha El-Tawab, Abdulaziz Hamada, Rehab Elhagracy, Karen Pinto, Salem Alshemmari

Hematology/Oncology and Stem Cell Therapy

Primary central nervous system lymphoma (PCNSL) is a rare lymphoma that involves the central nervous system. The standard treatment involves chemotherapy with high-dose methotrexate. To the best of our knowledge, this is the first reported case of employing checkpoint inhibitor, nivolumab, alone to treat a patient with PCNSL who could not tolerate the induction therapy. In aggressive cases of PCNSL where chemotherapy may become futile, stand-alone checkpoint inhibitors should be considered as the front-line treatment protocol.

Predictors And Management Of Relapse To Axicabtagene Ciloleucel In Patients With Aggressive B-Cell Lymphoma, Jose Vicente Forero-Forero, Paula A. Lengerke-Diaz, Eider Moreno-Cortes, Megan Melody, Zaid Abdel Rahman, Allison C. Rosenthal, Mohamed A. Kharfan-Dabaja, Januario E. Castro

Hematology/Oncology and Stem Cell Therapy

Objective/background: Despite the success of chimeric antigen receptor (CAR) T-cell therapy in patients with aggressive non-Hodgkin lymphoma (aNHL), some patients still fail treatment, and their prognosis is dismal. Methods: We performed a retrospective study of aNHL patients treated with axicabtagene ciloleucel (axi-cel) at two Mayo Clinic centers between 2018 and 2020. We evaluated predictive factors, toxicities, and responses to salvage regimens after CAR T-cell therapy. Results: Thirty-four patients received axi-cel with a median length of hospitalization of 14 days. Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome of any grade occurred in 91% and 41% of patients, respectively. …

Immune Checkpoint Inhibitor-Induced Pneumonitis: Incidence, Clinical Characteristics, And Outcomes, Harsha Banavasi, Seongho Kim, Samer Alkassis, Asil Daoud, Amir Laktineh, Misako Nagasaka, Ammar Sukari, Ayman O. Soubani

Hematology/Oncology and Stem Cell Therapy

Background: Immune checkpoint inhibitors (ICIs) are the newest class of anticancer drugs. Pneumonitis is increasingly being recognized as a potential complication of these agents. Methods: We conducted a retrospective study of patients who received ICIs at a comprehensive cancer center. We collected data on demographics, type of malignancy, type of ICI agent, incidence of pneumonitis up to 6 weeks after receiving ICI agent, clinical characteristics, and risk factors for overall survival in patients who develop pneumonitis. Results: A total of 654 patients received ICIs during the study period. The most common type of cancer for which ICI was given was …

Changes In Heme Levels During Acute Vaso-Occlusive Crisis In Sickle Cell Anemia, Evilazio Cunha Cardoso, Pedro Vieira Silva-Neto, Bidossessi Wilfried Hounkpe, Francine Chenou, Cintia Cristina Mateus Xerez Albuquerque, Nadja Pinto Garcia, Alexander Leonardo Silva-Junior, Adriana Malheiro, Purim Cesar, Franciele De Lima, Erich V. De Paula, Nelson Abrahim Fraiji

Hematology/Oncology and Stem Cell Therapy

Objective/Background: Sickle cell anemia (SCA) is associated with increased levels of extracellular heme, which is a key mediator of inflammation in this condition. Despite abundant evidence supporting this concept in cell and animal models, few studies addressed the association between heme levels and the development and severity of acute vaso-occlusive crises (VOC) in humans. Methods: A cross-sectional study was conducted in patients with acute VOC. Total extracellular heme levels were measured in both plasma and serum at admission and after convalescence, and correlated with other clinical and laboratory markers of SCA severity. Results: A total of 28 episodes of VOC …

Diagnosis And Treatment Of Subcutaneous Panniculitis-Like T-Cell Lymphoma: A Systematic Literature Review, Dunya Yunus Alsomali, Nasir Bakshi, Mohamed Kharfan-Dabaja, Riad El Fakih, Mahmoud Aljurf

Hematology/Oncology and Stem Cell Therapy

Objectives: The aim of this systematic review is to investigate different diagnostic methods and the available treatment options for subcutaneous panniculitis-like T-cell lymphoma (SPTCL). Methods: We searched PubMed, Web of Science, SCOPUS, EBSCO, and CINAHL Plus for published case reports of SPTCL. From each record, we extracted data of the diagnostic methods, immunohistochemical profile, clinical characteristics, and the treatment approaches provided. Data were summarized and narratively synthesized to highlight the various diagnostic methods and treatment options of SPTCL. Results: Our literature search yielded 1293 unique citations. Following screening, nine articles reporting a total of 15 cases were included in this …

Cross Fire: Daratumumab-Based Therapies Are Standard Of Care In Newly Diagnosed Multiple Myeloma, Neha Korde, Saad Z. Usmani

Hematology/Oncology and Stem Cell Therapy

There is no abstract.

Current Status And Future Perspectives On The Internet Of Things In Oncology, Ibrahim N. Muhsen, Omar W. Rasheed, Eiad A. Habib, Rakan K. Alsaad, Mohannad K. Maghrabi, Md A. Rahman, Douglas Sicker, William A. Wood, Muhammad S. Beg, Anthony D. Sung, Shahrukh K. Hashmi

Hematology/Oncology and Stem Cell Therapy

The Internet of Things (IoT) has penetrated many aspects of everyday human life. The use of IoT in healthcare has been expanding over the past few years. In this review, we highlighted the current applications of IoT in the medical literature, along with the challenges and opportunities. IoT use mainly involves sensors and wearables, with potential applications in improving the quality of life, personal health monitoring, and diagnosis of diseases. Our literature review highlights that the current main application studied in the literature is physical activity tracking. In addition, we discuss the current technologies that would help IoT-enabled devices achieve …

Efficacy And Safety Of Recombinant Thrombomodulin For The Prophylaxis Of Veno-Occlusive Complication In Allogeneiccit Hematopoietic Stem Cell Transplantation: A Systematic Review And Meta-Analysis, Richi Kashyap, Faiz Anwer, Muhammad Areeb Iqbal, Farhan Khalid, Anam Khan, Muhammad Ashar Ali, Muhammad Yasir Anwar, Anamika Chaudhary, Ali Jaan

Hematology/Oncology and Stem Cell Therapy

Background: Hepatic veno-occlusive disease (VOD), also termed as sinusoidal obstruction syndrome (SOS), is a lethal complication after hematopoietic stem cell transplantation (HSCT). Various factors put patients undergoing allogeneic HSCT at an increased risk for VOD. Thrombomodulin (TM) is an important factor which has a wide range of effects, including anticoagulant, anti-inflammatory, angiogenic, and protective effect, on endothelial cells. It plays a role in preventing excessive coagulation and thrombosis by binding with thrombin and inhibiting the coagulation cascade. There are a limited number of options for the prevention of this fatal complication. Recombinant thrombomodulin (rTM), an endothelial anticoagulant co-factor,

as prophylactic …

Strange Bedfellows: Npm1 Mutations In Acute Promyelocytic Leukemia, Stephen E. Langabeer

Hematology/Oncology and Stem Cell Therapy

No Abstract for this article type

Outcome Of Myeloma Patients With Covid-19 On Active Lenalidomide-Based Therapy: Does Lenalidomide Protect From Severe Covid-19?, Imran K. Tailor, Nawal F. Alshehry, Syed Z. Zaidi, Mohammed A. Marei, Ibraheem H. Motabi, Mansour Alfayez, Syed Y. Altaf

Hematology/Oncology and Stem Cell Therapy

No abstract for this article type.

Use Of Checkpoint Inhibitors In Gray Zone Lymphoma, Yensy Mariana Zelaya Rosales, Juliene Lima Mesquita, Yhasmine Delles Oliveira Garcia, Fernando Ricardo Fernandes Paz, Naiana Castelo Branco Campos, Joa˜O Paulo De Vasconcelos Leita˜O, Francisco Da´Rio Rocha Filho, Ricardo Vale Albino Oliveira Filho, Rome´Lia Pinheiro Gonc¸Alves Lemes, Fernando Barroso Duarte

Hematology/Oncology and Stem Cell Therapy

Checkpoint inhibitors, cancer immunotherapies, are the new forms of treatment for gray zone lymphoma, a rare subtype that combines the characteristics of both Hodgkin and non-Hodgkin disease forms. Programmed cell death protein 1/programmed cell death ligand 1 (PD-L1/PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) modulate the immune system function. Immunological checkpoints can be stimulatory or inhibitory, and tumors can use these checkpoints to protect against immune system attacks. This is a case report of a difficult diagnosis and describes the most current treatment using checkpoint inhibitors, through the review of the clinical record of a patient diagnosed with gray area …

High Expression Of Long Noncoding Rna Norad Is Associated With Poor Clinical Outcomes In Non-M3 Acute Myeloid Leukemia Patients, Mohammad Masoud Eslami, Mina Soufizomorrod, Mohammad Ahmadvand

Hematology/Oncology and Stem Cell Therapy

Objective/Background: Dysregulation of long noncoding RNA NORAD has been identified in human solid tumors. However, the expression profile of NORAD and its clinical implications in acute myeloid leukemia (AML) is unclear. The current study aimed to explore the NORAD expression status and its clinical significance in non-M3 AML patients. Methods: NORAD expression was evaluated in 60 de novo non-M3 AML patients and 49 healthy individuals using quantitative reverse transcription–polymerase chain reaction method. The correlation between NORAD transcription levels and clinicopathologic characteristics was statistically studied. Results: Compared with the healthy controls, NORAD was consistently higher in non-M3 AML patients (p = …

Prophylactic Pretransplant Ganciclovir To Reduce Cytomegalovirus Infection After Hematopoietic Stem Cell Transplantation, Daniel R. Reed, Gina R. Petroni, Melissa West, Caroline Jones, Abeer Alfaraj, Paige G. Williams, Kathlene Degregory, Kyle Grose, Sandra Monson, Indumathy Varadarajan, Leonid Volodin, Gerald R. Donowitz, Tamila L. Kindwall-Keller, Karen K. Ballen

Hematology/Oncology and Stem Cell Therapy

Objective/Background: Cytomegalovirus (CMV) reactivation remains a serious complication after allogeneic hematopoietic cell transplantation (HCT) occurring in approximately 60–70% of CMV-seropositive HCT recipients. CMV reactivation leads to adverse outcomes including end-organ damage, graft-versus-host disease, and graft failure. Methods: Ganciclovir was administered pretransplant at 5 mg/kg twice daily intravenously from the start of conditioning to Day T-2 to CMV-seropositive patients receiving their first allogeneic HCT. CMV DNA was monitored weekly until at least Day 100 posttransplant. Results: A total of 109 consecutive patients were treated, median age 57 (range 20–73) years. Of these, 36 (33%) patients had a CMV reactivation within the …

Azacitidine Maintenance Therapy Postallogeneic Stem Cell Transplantation In Poorrisk Acute Myeloid Leukemia, Amany R. Keruakous, Jennifer Holter-Chakrabarty, Sarah A. Schmidt, Mohamad O. Khawandanah, George Selby, Carrie Yuen

Hematology/Oncology and Stem Cell Therapy

Objective/Background: Allogeneic hematopoietic stem cell transplant (HSCT) is the potential curative modality for poor-risk acute myeloid leukemia (AML), relapse remains the main reason for transplant failure. Early-phase studies showed azacitidine is safe for post-transplant maintenance therapy in AML. Methods: We performed a single institutional prospective cohort study to evaluate the benefit of azacitidine maintenance therapy following allogeneic HSCT in poor-risk AML. The main objective of this study is to generate a hypothesis aiming to optimize post-transplantation outcomes in poor-risk AML. Forty-nine adults with poor-risk AML who underwent allogeneic HSCT were evaluated in a nonrandomized prospective cohort fashion. Thirty-one participants received …

Current Practice Of Oral Care For Hematopoietic Stem Cell Transplant Patients: A Survey Of The Eastern Mediterranean Blood And Marrow Transplantation Group, Hani Mawardi, Nathaniel Treister, Osama Felemban, Waleed Alamoudi, Ghada Algohary, Abdulrahman Alsultan, Nawal Alshehri, Illias Tazi, Marwan Shaheen, Mohamed Alsharani, Salem Alshemmari, Mutlu Arat, Mohamed Amine Bekadja, Murtadha Al-Khabori, Samar Okaily, Natasha Ali, Husam Abujazar, Wasil Jastaniah, Amir Ali Hamidieh, Sharukh Hashmi, Mahmoud Aljurf

Hematology/Oncology and Stem Cell Therapy

Introduction: The oral cavity is one of the most common sites impacted by hematopoietic stem cell transplantation (HSCT) with acute complications including mucositis, bleeding, salivary gland dysfunction, infection, and taste alteration. These complications may result in significant morbidity and can negatively impact outcomes such as length of stay and overall costs. As such, oral care during HSCT for prevention and management of oral toxicities is a standard component of transplant protocols at all centers. The objective of this study was to evaluate the current oral care practices for patients during HSCT at different transplant centers within the Eastern Mediterranean region. …

Outcomes Of Patients With Thrombocytopenia Evaluated At Hematology Subspecialty Clinics, Zaid H. Abdel Rahman, Kevin C. Miller, Hiba Jabbour, Yaser Alkhatib, Vijaya Donthireddy

Hematology/Oncology and Stem Cell Therapy

Background: Thrombocytopenia is a frequently encountered laboratory abnormality and a common reason for hematology referrals. Workup for thrombocytopenia is not standardized and frequently does not follow an evidence-based algorithm. We conducted a systematic analysis to evaluate the laboratory testing and outcomes of patients evaluated for thrombocytopenia at hematology clinics in a tertiary referral center between 2013 and 2016. Patient and methods: We performed a comprehensive chart review for patients evaluated for thrombocytopenia during the study period. Patients were followed for 1 year from the initial hematology evaluation and assessed for the development of a hematologic malignancy, rheumatologic, or infectious diseases …

Therapeutic Roles Of Antibody Drug Conjugates (Adcs) In Relapsed/Refractory Lymphomas, Hamza Hashmi, Alicia Darwin, Taiga Nishihori

Hematology/Oncology and Stem Cell Therapy

Relapsed or refractory lymphoma is commonly treated with combination chemoimmunotherapy and cellular immunotherapy. Modest response rates and associated toxicities are obstacles to achieving durable remission using traditional cytotoxic chemotherapy, especially in frail patients with advanced disease. Antibody drug conjugates represent a new class of novel targeted agents with significant improvement in therapeutic efficacy in the treatment of lymphomas. Several of these agents, which offer improved targeting, greater potency, and better therapeutic index over traditional chemotherapy, are changing the treatment landscape for lymphomas and other hematological malignancies. Despite the therapeutic potential of these agents, the delivery and release of cytotoxic agents …

Radiotherapy And Immunotherapy In Melanoma Brain Metastases, Amir Anvari, Pegah Sasanpour, Mania Rajabzadeh Kheradmardi

Hematology/Oncology and Stem Cell Therapy

Background and objective: Melanoma brain metastasis (MBM) generally portends a dismal prognosis. Simultaneous use of radiotherapy (RT) and immune checkpoint inhibitor (ICI) therapy demonstrated tremendous promise and emerged as the new standard. This meta-analysis was conducted to evaluate survival outcomes and toxicities of this combination in patients with MBM. Data analyses were performed using Comprehensive Meta-Analysis software (version 2) and IBM SPSS software (version 27). Methods: A systematic literature search of PubMed, EMBASE, and the Cochrane Library (via Wiley) was conducted using PICOS/PRISMA selection protocol and included studies to evaluate survival and safety-associated outcomes of ICI + RT for the …

Outcomes Of Patients Diagnosed With Chronic Lymphocytic Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: Results From A Tertiary Care Center, Swe Mar Linn, Ram Vasudevan Nampoothiri, Carol Chen, Ivan Pasic, Zeyad Al-Shaibani, Wilson Lam, Arjun Datt Law, Fotios V. Michelis, Dennis D.H. Kim, Armin Gerbitz, Jeffrey Lipton, Rajat Kumar, Jonas Mattsson, Auro Viswabandya

Hematology/Oncology and Stem Cell Therapy

Background: Allogeneic hematopoietic stem cell transplantation (allo-HCT) is currently the only curative treatment for patients with chronic lymphocytic leukemia (CLL). Methods: We analyzed the outcomes of 93 patients (median age: 52 years) who underwent allo-HCT at our center between 1989 and 2019. Results: After a median follow-up of 35 months, relapse was observed in 15.1% (n = 14) patients. The estimated 2-year non-relapse mortality, relapse-free survival, and overall survival (OS) were 38.1%, 54.2%, and 58.7%, respectively. The ECOG performance status 2 (hazard ratio [HR]: 4.1; p = .001) and use of total body irradiation (in a myeloablative conditioning regimen; HR: …

Unique Aspects Of Graft-Versus-Host-Disease Management In The Eastern Mediterranean Region: Report From The Eastern Mediterranean Blood And Marrow Transplantation Group: Special Report, Shahrukh Hashmi, Marwan Shaheen, Salman Adil, Parvez Ahmed, Syed Ahmed, Nour Ben Abdeljelil, Amal Alabdulwahab, Amal Albeihany, Saad Aldaama, Murtadha Al-Khabori, Salam Alkindi, Fahad Almohareb, Ahmed Alsaeed, Amal Alseraihy, Salem Alshemari, Mouhab Ayas, Naeem Chaudhri, Waleed Da’Na, David Dennison, Asma Elquessar, Alaa Elhaddad, Ahmad Ibrahim, Hasan Hashem, Wasil Jastaniah, Hani Mawardi, Amr Nassar, Tariq Satti, Lamia Torjemane, Khalid Tabbara, Hassan El Solh, Bassim Albeirouti, Mahmoud Aljurf

Hematology/Oncology and Stem Cell Therapy

Ther is no abstract for this article type.

The Impact Of Beta-Blocker Use At The Time Of Hematopoietic Cell Transplantation On The Development Of Acute And Chronic Graftversus- Host Disease, Arjun Patel, Guru Subramanian Guru Murthy, Mehdi Hamadani, Aniko Szabo, Jennifer M. Knight

Hematology/Oncology and Stem Cell Therapy

Sympathetic nervous system activation plays a role in the development of acute and chronic graft-versus-host disease (GVHD) following allogeneic hematopoietic cell transplantation (HCT). Primary objective was to compare the cause-specific hazard of grade II-IV and III-IV acute GVHD (aGVHD) and chronic GVHD (cGVHD) in the context of ß-blocker use and type (selective vs. non-selective). Secondary objectives included overall survival (OS), relapse-free survival (RFS), and cumulative incidence of relapse, non-relapse mortality (NRM), and grade II-IV and III-IV aGVHD and cGVHD. The current study included 151 patients ages 18 and older diagnosed with hematological malignancies who underwent reduced intensity conditioning allogeneic HCT …

Effects Of Different Types Of Allogeneic Hematopoietic Stem Cell Transplantation Donors On Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia During The Tyrosine Kinase Inhibitor Era: A Systematic Review And Meta-Analysis, Ben Ponvilawan, Weerapat Owattanapanich, Nipith Charoenngam, Smith Kungwankiattichai

Hematology/Oncology and Stem Cell Therapy

Background: Matched donor (MD) allogeneic hematopoietic stem cell transplantation (allo- HSCT) is currently the preferred choice of treatment for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) patients who have achieved complete remission. This systematic review and meta-analysis was conducted to investigate the effects of allo-HSCTs from different donor types for Ph+ ALL patients who received tyrosine kinase inhibitors (TKIs). Methods: Studies in EMBASE and MEDLINE between inception and December 2020 were identified using search terms related to ‘‘Ph+ ALL” and ‘‘HSCT.” Eligible studies were studies with Ph+ ALL patients who received a TKI and allo-HSCT. The primary outcomes of interest—the …

Fam-Trastuzumab Deruxtecan (Enhertu) Induced Pyloric Perforation In Hormonal Receptor Positive/ Her2 Low Express Metastatic Breast Cancer., Taher Al-Tweigeri

Hematology/Oncology and Stem Cell Therapy

There is no abstract for this article.

Improved Quality Of Life Of Sickle Cell Disease Patients Post Allogeneic Stem Cell Transplant: Another Indication For Transplant, Bader Ali Aljaafri, Mohammad Fahad Albawardi, Abdulaziz Yahya Alghamdi, Khaled Mohammad Altowairgi, Yazeed Saleh Alhoshan, Bader Alahmari, Husam Alsadi, Mazin Ahmed, Mohammed Alnahdi, Zied Aljubour, Mohsen Alzahrani

Hematology/Oncology and Stem Cell Therapy

Introduction: Sickle Cell Disease (SCD) is among the most frequently inherited diseases worldwide. The severity of SCD ranges from mild to severe, and the disease involves multiple complications, including pulmonary hypertension, stroke, recurrent vaso-occlusive crises, end-organ damage, and an increased mortality risk. Allogeneic hematopoietic cell transplantation (HCT) is potentially a curative option for patients with SCD.

Objectives of the Study: The study objective was to assess the quality of life of adolescent and adult SCD patients receiving HCT pre-and post-transplant.

Methods: An analytical cross-sectional study was conducted. SCD patients with at least one year of follow-up after HCT were interviewed …

Oxidative Stress And Hepcidin Expression In Pediatric Sickle Cell Anemia With Iron Overload, Eman A. Elbostany, Eman A. Elghoroury, Eman H. Thabet, Alaa A. Rashad, Enas A. Rasheed, Gamila S.M. El-Saeed, Dalia A. Abdelhalim, Safa N. Abdelfattah, Iman I. Salama, Niveen Salama

Hematology/Oncology and Stem Cell Therapy

Background: Blood transfusion (BT) is essential in treating sickle cell disease (SCD); however, it leads to iron overload (IO) and oxidative stress. We studied the relationship between oxidative stress, iron status parameters, hepcidin mRNA gene expression, and IO in SCD patients. Methods: We classified all SCD patients (n = 90) into two groups: Group I, 45 children (s.ferr itin 938 ng/mL) and Group II, 45 children (s.ferritin < 938 ng/mL). A total of 55 children, age and sex matched, participated as a control group. Malondialdehyde (MDA), nitrite, s.iron, s.total iron-binding capacity (sTIBC), transferrin saturation %, s.ferritin, s.hepcidin, and hepcidin mRNA gene expression were assessed. Results: Among SCD BT-dependent patients (>3 times/year), 63% were from Group I and 37% from Group II, p < .01. The two patient groups had significantly lower s.hepcidin and hepcidin gene expression than controls (p < .001). TIBC, s.iron, s.ferritin, transferrin saturation %, ferritin/ hepcidin ratio, and MDA levels were higher among SCD patients than controls (p < .001).

Group I had higher mean level of ferritin/hepcidin ratio and MDA than Group II (p < .01). The higher level of MDA and increased frequency of BT were the significant predicting risk factors for IO (p < .05). A receiver-operating characteristic curve indicates that MDA is the outstanding significant biomarker for high level of s.ferritin with subsequent IO progression. Conclusion: MDA may serve as a biomarker of oxidative stress and IO in SCD patients. This result paid attention for urgent initiation of antioxidant and chelation therapy on detecting increased MDA level.

Therapy-Related Acute Myeloid Leukemia In Non-Hodgkin Lymphoma Survivors: Risk, Survival Outcomes And Prognostic Factor Analysis, Utsav Joshi, Adheesh Bhattarai, Suman Gaire, Pravash Budhathoki, Vishakha Agrawal, Roshan Subedi, Bishesh Sharma Poudyal, Prajwal Dhakal, Ronald Sham, Vijaya Raj Bhatt

Hematology/Oncology and Stem Cell Therapy

Background: Therapy-related acute myeloid leukemia (tAML) is a serious complication in patients with Non-Hodgkin lymphoma (NHL) exposed to chemotherapy or radiation. This large database study aims to quantify the risk of tAML in NHL, and determine the impact of tAML on overall survival (OS) of patients with NHL. Materials and Methods: Patients diagnosed with NHL and de novo AML from 2009 to 2018 were identified from the Surveillance, Epidemiology, and End Results database. Multiple primary standardized incidence ratio (SIR) sessions of the SEER*Stat software were used to calculate SIR and absolute excess risk of tAML. Overall survival (OS) was evaluated …

Tumor Seeding Post Nutritional Support Implementation: A Rare Complication; A Scoping Review, Jumanah S. Alawfi, Reem M. Ragea, Sadeem S. Alrubaian

Hematology/Oncology and Stem Cell Therapy

Cancer patients are at risk of malnutrition because of reduced intake that may occur as results of the disease itself or the treatment; making the oral intake a challenging task. Thus, nutritional support (NS) is used to deliver their nutrient requirements. Feeding tube site implantation for cancer patients has been reported after endoscopic feeding gastrostomy installation. This manuscript undertakes a structured database review to better understand this phenomenon. A structured search strategy was applied with Boolean operators for retrieving data from six search engines and selected reference lists. Thirty-three records were included. It found that the most common research design …

What Are Factors Influencing On Life Space Mobility In Cancer Survivors After Hematopoietic Stem Cell Transplantation? -Physical Function, Depression, Fatigue, Neighborhood Walkability, Or Employment Status?, Junichiro Inoue, Takashi Saito, Daisuke Makiura, Rei Ono, Hisayo Doi, Kimikazu Yakushijin, Yoshitada Sakai

Hematology/Oncology and Stem Cell Therapy

Background/Objective: The amount of physical activity in daily life is important to maintain the physical and mental health of cancer survivors after hematopoietic stem cell transplantation (HSCT). As the physical activity is considered to be limited by the life space mobility (LSM), it is more important to maintain and expand the LSM in post-HSCT survivors. The purpose of this study was to clarify the factors that affect the LSM in post-HSCT survivors. Methods: Thirty cancer survivors after HSCT (14 women, mean age 52.0±12.3 years, 196-3,017 days post-HSCT) were included in this cross-sectional study. Patient characteristics, employment status, life space (Life …

Evaluation Of Janus Kinase 2 Exon 12 Mutations In Patients With Jak2v617f-Negative Polycythemia Vera, Sahar Khosravi, Bahram Chahardouli, Pouyan Ebrahimi, Fatemeh Naghdi Babaei, Kamran Alimoghadam, Shahrbano Rostami

Hematology/Oncology and Stem Cell Therapy

Background and Objectives: Polycythemia vera (PV) is an acquired and clonal stem cell disorder characterized by abnormal erythropoiesis. The identification of a unique Janus kinase 2 (JAK2) gene mutation that leads to increased activity of the protein in patients with chronic myeloproliferative disorders has provided a beneficial diagnostic marker. In this study, we evaluated JAK2 exon 12 mutations in V617F-negative patients with PV.

Patients and Methods: We conducted a cross-sectional study of patients with PV who had been referred to Shariati Hospital (Tehran, Iran) between 2013 and 2016. We tested all samples for leukemia and cell line using flow cytometry. …